4basebio UK Societas Notice of AGM and Posting of Accounts
June 04 2021 - 1:00AM
UK Regulatory
TIDM4BB
4basebio UK Societas
(the "Company")
Notice of Annual General Meeting
Posting of Annual Report and Financial Statements
4basebio UK Societas (AIM: 4BB), the specialist life sciences group focused on
exploiting intellectual property in the field of gene therapies and vaccines,
confirms that the Annual Report and Accounts for the year ended 30 December
2020, and the Notice of Annual General Meeting ("AGM") with accompanying Form
of Proxy has been posted to shareholders today.
These documents are also available, in electronic form, for download on the
Company's website: https://www.4basebio.com/investors/.
The Company's AGM will be held at 09:00 a.m. on Wednesday, 30 June 2021 at the
Company's offices at 25 Norman Way, Over, CB24 5QE. This will be followed by a
presentation from the Company through the Investor Meet Company platform on 1
July 2021 at 10am. Investors can sign up to Investor Meet Company for free and
register interest here: https://www.investormeetcompany.com/
4basebio-uk-societas/register-investor
The Company continues to monitor developments relating to the outbreak of
COVID-19, including the related public health guidance and legislation issued
by the UK Government as well as the "roadmap out of lockdown" published on 22
February 2021. At present, it is expected that it will be possible to hold a
physical AGM and to welcome the maximum number of shareholders we are able
within safety constraints and in accordance with government guidelines that
will apply at the time.
However, given the constantly evolving nature of the situation, we want to
ensure that we are able to adapt these arrangements efficiently to respond to
changes in circumstances. On this basis, should the situation change such that
we consider that it is no longer possible for shareholders to attend the
meeting, we will adopt contingency plans and notify shareholders of the change
via an RNS announcement as early as is possible before the date of the
meeting. Such contingency plans are likely to result in the holding of a
virtual or hybrid meeting. Any updates to the position will also be included
on our website at https://www.4basebio.com/investors/. Should we have to change
the arrangements in this way, it is likely that we will not be in a position to
accommodate shareholders beyond the minimum required to hold a quorate meeting
which will be achieved through the attendance of employee shareholders.
Shareholders intending to attend the AGM, should this be possible, are asked to
register their intention as soon as practicable (and the Company strongly
encourages them to advise the Company at least 48 hours in advance of the
meeting) by emailing the Company Secretary at david.roth@4basebio.com. Any such
communication shall not provide a guarantee that admittance to the AGM will be
permitted where to do so would be in breach of rules governing public
gatherings and/or the need to protect the health and safety of those already in
the meeting.
Given the uncertainty around whether shareholders will be able to attend the
AGM because of tighter restrictions due to a change in the situation with the
COVID-19 pandemic, we encourage all shareholders to complete and return the
accompanying Form of Proxy appointing the Chair of the meeting as their proxy
(or appoint the Chair as their proxy through CREST). This will ensure that your
vote will be counted if ultimately you (or any other proxy you might otherwise
appoint) are not able to attend the meeting.
For further enquiries, please contact:
4basebio UK Societas +44 (0)12 2396 7943
Heikki Lanckriet, CEO
Cairn Financial Advisers LLP (Nominated +44 (0)20 7213 0880
Adviser)
Jo Turner / Sandy Jamieson
finnCap Ltd (Broker) +44 (0)20 7220 0500
Geoff Nash/Richard Chambers/Charlotte
Sutcliffe
Walbrook PR +44 (0)20 7933 8780 or
4basebio@walbrookpr.com
Anna Dunphy / Paul McManus Mob: +44 (0)7876 741 001 / +44 (0)7980 541
893
Notes to Editors
4basebio (AIM: 4BB) is a specialist life sciences group focused on therapeutic
DNA for gene therapies and DNA vaccines and providing solutions for effective
and safe delivery of these DNA based products to patients. It is the intention
of the Company to become a market leader in the manufacture and supply of high
purity, synthetic DNA for research, therapeutic and pharmacological use. The
immediate objectives of 4bb are to validate and scale its DNA synthesis and
advance its collaborations to facilitate the functional validation of its DNA
based products and gene delivery solutions.
The Company divested from 4basebio AG ("4bb AG"), a German company listed on
the Prime Standard segment of the Frankfurt Stock Exchange, following the
disposal by 4bb AG (then named Expedeon AG) of its proteomics and immunology
business to AIM-quoted Abcam plc in January 2020 for ?120million. Following the
disposal, 4bb AG retained its genomics business which owned and licensed
certain intellectual property including its proprietary, patent-protected
technology, TruePrimeT. This is the foundation for building the Company's
synthetic DNA manufacturing business which 4bb AG transferred to the Company
along with funding to continue the Company's development and investment.
END
(END) Dow Jones Newswires
June 04, 2021 02:00 ET (06:00 GMT)
4basebio (LSE:4BB)
Historical Stock Chart
From Mar 2024 to Apr 2024
4basebio (LSE:4BB)
Historical Stock Chart
From Apr 2023 to Apr 2024